Subgroups of adult-onset diabetes: a prospective follow-up study of progression of insulin resistance and deficiency and association with liver steatosis and fibrosis

Short running title: Cluster-stability in diabetes subgroups

Aleksi Laitinen [1-3*], Annemari Käräjämäki [1,4*], Aki J Käräjämäki [5], Samu Kurki [1,8], Liisa Hakaste [1,6], Olof Asplund [7], Johan Hultman[7] , Kaj Lahti [4], Mikko Lehtovirta [1,6], Emma Ahlqvist [1,7], Tiinamaija Tuomi [1,6-8]

*Equal contribution

Affiliations: [1]Institute for Molecular Medicine Finland and Research Program of Clinical and Molecular Medicine, University of Helsinki, Helsinki, Finland, [2]Department of Endocrinology, Vaasa Central Hospital, Wellbeing Services Area of Ostrobothnia, Vaasa, Finland, [3]Department of Endocrinology, Turku University Hospital, Turku, Finland, [4]Diabetes Unit of Ostrobothnia, Wellbeing Services County of Ostrobothnia, Vaasa, Finland, [5]Department of Gastroenterology and Hepatology, Vaasa Central Hospital, Wellbeing Services of County of Ostrobothnia, Vaasa, Finland, [6]Folkhälsan Research Center, Helsinki, Finland, [7]Lund University, Malmö, Sweden, [8]Helsinki University Hospital, Helsinki, Finland

Corresponding author: Tiinamaija Tuomi, Helsinki University Hospital, Abdominal Center, Endocrinology, PO Box 340, FIN-00029 Helsinki, Finland; tiinamaija.tuomi@hus.fi tel. +358 504279013)

4349 words, 2 tables, 2 figures

Key words: cluster analysis, insulin resistance, liver disease, insulin secretion, liver fat, subtypes, glucagon stimulation

TWITTER SUMMARY

Diabetes consists of heterogenous disease phenotypes, and disease stratification could improve targeting of interventions. Previously, we suggested dissecting adult-onset diabetes into five cluster-based subgroups using six easily accessible variables (GAD-antibodies, BMI, age, HbA1c, HOMA2-B and HOMA2-IR) measured at or near diagnosis. In this study, we assessed changes in insulin secretion and sensitivity, stability of subgroup assignment and association of steatotic liver disease (SLD) and liver fibrosis (LF) with tissue insulin resistance 2-10 years after diagnosis. Differences between subgroups attenuated during follow-up. In the obesity and age-related subgroups (MOD & MARD) >76% were assigned to the original cluster when classified at follow-up, whereas this was true for <25% of the groups characterized by insulin deficiency or resistance (SIDD & SIRD). HOMA2-B and HOMA2-IR decreased significantly but were still highest in the SIRD group at the follow-up visit. SLD/LF were most common in SIRD and MOD, with differences compared to other subgroups mainly explained by BMI. LF was also associated with insulin resistance in liver, adipose tissue and muscle, independently of BMI or SLD. Cluster assignment performed near diagnosis is thus preferred, as phenotypic features attenuate with time. Insulin resistance should be evaluated when assessing the risk of LF in individuals with diabetes.

ABSTRACT

OBJECTIVE

To assess changes in insulin secretion and sensitivity in subgroups of adult-onset diabetes (derived from cluster analysis of GADA-positivity, BMI, age, HbA1c, HOMA2-B and HOMA2-IR), the stability of the subgroup assignment, and the association between steatotic liver disease (SLD), liver fibrosis (LF) and tissue insulin resistance.

RESEARCH DESIGN AND METHODS

Participants registered in a regional diabetes register within three years from diagnosis, were restudied 2-10 years later with fasting laboratory tests and a questionnaire (n=547). A subset (n=194) participated in a clinical investigation including estimation of insulin secretion and sensitivity with i.v. glucagon-insulin tolerance test, and SLD/LF with elastography.

RESULTS

Differences between subgroups attenuated during the follow-up. Obesity and age-related subgroups (MOD & MARD) were most stable with >76% assigned to the same cluster at registration and follow-up, whereas that hold for <25% in the groups characterized by insulin deficiency or resistance (SIDD & SIRD). Despite stable BMI, HOMA2-B and HOMA2-IR decreased significantly during follow-up but remained highest in the SIRD group. Prevalence of SLD/LF was highest in SIRD (70%/42%) and MOD (60%/41%). The differences between subgroups were mainly explained by BMI. However, LF was associated (OR [95% CI]) with insulin resistance in liver (3.90 [2.05-7.42]; p<0.001), adipose tissue (1.14 [1.06-1.22]; p<0.001]) and muscle (0.33 [0.17-0.64]; p<0.001), independently of BMI or SLD.

CONCLUSIONS

Cluster assignment should be performed near diagnosis, as the more severe phenotypic features attenuate with time (or treatment). To assess the risk of LF in individuals with diabetes, the degree of insulin resistance should be evaluated, not only BMI.

ARTICLE HIGHLIGHTS

a) We investigated cluster-stability, liver health and changes in insulin resistance and insulin deficiency in cluster-based diabetes subgroups

b) Are there differences between subgroups? Does insulin resistance associate with liver steatosis and fibrosis in subgroups of diabetes?

c) We observed a major shift towards the more common obesity and age-related clusters after the follow-up. Liver fibrosis was mainly associated with insulin-resistant and obesity-related subgroups and, independently of BMI or liver steatosis, with insulin resistance of different tissues.

d) The phenotypic features of the subgroups attenuate with time and treatment, indicating the need for clustering to be performed at diagnosis.

GRAPHICAL ABSTRACT

We aimed to investigate cluster-stability, insulin resistance, insulin deficiency and liver health in cluster-based subgroups of adult-onset diabetes 2-10 years after diagnosis

Recruitment criteria

1) Registration <3y from dg
2) Duration of DM 2-10y
3) Age 18-80y

Clustering variables

GADA
BMI
HbA1c
Age
HOMA2-B,
HOMA2-IR

SAID = Severe autoimmune diabetes
SIDD = Severe insulin deficient diabetes
SIRD = Severe insulin-resistant diabetes
MOD = Moderate obesity-related diabetes
MARD = Moderate age-related diabetes

547 individuals with diabetes were reclustered

194 individuals with diabetes participated to follow-up visit

Liver steatosis and fibrosis were measured using vibration controlled transient elastography

Insulin resistance of different tissues was assessed

HOMA2-IR (liver)
Insulin (0.05 IU/kg) tolerance test (muscle)
Adipo-IR (adipose tissue)

Most in the MOD (76%) and MARD (91%) groups kept their original cluster, whereas most SIDD and SIRD patients were reallocated to other clusters

Clusters other than SAID did not differ in muscle insulin sensitivity

SIRD had highest insulin response to iv-glucagon

Liver fibrosis was associated with insulin resistance of different tissues independently of BMI or liver steatosis, and the presence was nominally highest in SIRD and MOD

SIRD
MOD
Muscle insulin sensitivity
Adipose tissue insulin resistance
Liver fibrosis
Hepatic insulin resistance

Created in BioRender. Laitinen, A. (2025) https:// BioRender.com/mu7w50r

INTRODUCTION

Adult-onset diabetes includes heterogenous disease phenotypes and multiple metabolic dysfunctions, but these translate only partially into different treatment or follow-up trajectories. In 2018, we suggested five subgroups based on presence of GAD-antibodies (GADA) and a cluster-analysis of five clinical variables measured at or near diagnosis of diabetes: HbA1c, age at diagnosis, BMI and estimates of insulin secretion and -resistance at fasting (homeostasis model assessment 2, HOMA2-B and HOMA2-IR, respectively). [1]

Positive GADA defines severe autoimmune diabetes (SAID), including type 1 diabetes and latent autoimmune diabetes in adults (LADA). Those grouped as SAID or GADA-negative severe insulin-deficient diabetes (SIDD) have decreased insulin secretion and marked hyperglycemia. Conversely, individuals grouped as moderate obesity- (MOD) or age-related (MARD) diabetes along with severe insulin-resistant diabetes (SIRD) are diagnosed with only slightly elevated HbA1c levels.

The subgroups differed in terms of the risk of comorbidities [1,2]. In particular, the SIRD group had earlier and more prevalent kidney disease, and the SIDD and SIRD groups had the highest age- and sex-adjusted risk of incident nephropathy and myocardial infarction, despite a difference in glycemic level. The SIRD group also seemed to have steatotic liver disease (SLD) more often, based on recorded ICD-codes, ALT [2] as well as MRI imaging in a small study [3]. Insulin resistance is known to increase the risk of liver steatosis, fibrosis and cirrhosis, [4,5] which are associated with cardiovascular events and mortality. [6,7]

While these subgroups have been replicated in multiple cohorts, [8] little is known about the progression of insulin deficiency and resistance over time [3] or association with insulin resistance in different tissues (liver, muscle and adipose tissue). These aspects could aid in dissecting the pathophysiological factors contributing to the heterogeneity of diabetes [9], and inform targeted treatment and follow-up of diabetes [10] and the liver comorbidities. [11–14]

In this prospective follow-up study, we studied progression of insulin deficiency and resistance as well as the stability of the cluster assignment during the follow-up. Moreover, we compared fasting and stimulated measures of insulin secretion and action, as well as the association between SLD, LF and insulin resistance in different tissues overall and within the subgroups of diabetes.

RESEARCH DESIGN AND METHODS

Study population

The Diabetes registry of Vaasa (DIREVA) is a Finnish regional study aiming at recruiting all individuals with diabetes in the Vaasa Hospital District since 2007. At the end of 2023, of about 10 000 adults with diabetes in the region, 8187 with any type of diabetes had been registered (with signed consent) by diabetes nurses and provided blood samples [DIREVA lab-1: HbA1c, fasting plasma glucose (FPG) and serum/plasma C-peptide (S/P-Cpe)]. Ethics committees of Vaasa Hospital District, the Wellbeing Services County of Southwest Finland (VARHA/2406/13.02.02/2024) and the Hospital District of Southwest Finland (ETMK Dnro:48 /1801/2014) approved the study.

The follow-up study included 547 individuals (Figure S1): Group$_A$, 500 individuals with questionnaire data and new laboratory samples; Group$_B$, 194 individuals participating in a follow-up study visit (overlap between groups, N=147). The inclusion criteria were: 1) age at diagnosis of diabetes ≥18 years (and ≤80 years in Group$_B$); 2) registration data within 3 years from diagnosis to assign the cluster subgroups [1] (BMI, age at diagnosis, and DIREVA lab-1); 3) time-difference of 2-10 (Group$_A$) or 3-10 (Group$_B$) years from the registration. We invited all individuals fulfilling the criteria for Group$_A$, and all those belonging to the SAID, SIDD, and SIRD subgroups and a random sample from the MOD and MARD subgroups for Group$_B$. The cluster-based subgroups were assigned using the ANDIS cohort [1] as a reference group.

All participants were sent a questionnaire (including, but not restricted to, questions on self-measured weight and waist circumference, medication, weight development, and alcohol consumption), and fasting blood samples were drawn for the same tests as at registration (DIREVA lab-1), as well as for serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), glutamyl transferase (GT), creatinine, lipids, and blood hemoglobin (Hb), leukocytes and platelets (DIREVA lab-2).

Study visit (Group$_B$)

A research nurse measured the weight, height, waist and hip circumference, heart rate, blood pressure, and fat free mass (Body composition analyzer BF-350, Tanita). Fasting (10-12 hours) venous blood samples were drawn for DIREVA lab-1/2, serum/plasma insulin, glucagon, GADA and IA-2A (Islet antigen-2 antibodies), followed by a combined i.v. glucagon and insulin tolerance test (GITT). [15] An i.v. bolus of 0.5 mg glucagon was administered at 0 min and of insulin aspart (0.05 IU/kg diluted to 10 IU/ml, NovoNordisk, Bagsværd, Denmark) at 40 min. Blood samples were drawn for PG at 0, 40, 45, 51 and 60 min, and for S-Cpe at 0 and 6 min. Insulin sensitivity was estimated using the first-order rate constant for glucose disappearance between 40 and 60 min (K_{ITT}=ln $2/T_{1/2}$x100). [15]

The exclusion criteria for glucagon administration were FPG >10 mmol/l, previous measurement of S-Cpe <0.2 nmol/l, insulin pump therapy, systolic blood pressure >200 or diastolic >110 mmHg, or questionnaire replies indicating risk of heart-related adverse effects.

In case of insulin-treatment (30 individuals), the basal insulin was continued, but the morning dose of glargine 100 IU/ml, detemir or biphasic insulin aspart was postponed until after the tests; the insulin pump dosage was reduced by 20% one hour before the examination. Liraglutide and exenatide (N=5) were paused 2 days, semaglutide (N=23) one week, and oral glucocorticoids one

month before the study. On the morning of the visit, participants did not take any medications besides anticoagulants.

We excluded individuals from some analyzes (Fig S1b) due to previous obesity surgery, liver metastasis of endocrine tumor, or being extreme outliers.

Liver fat content and liver fibrosis (Group_B)

On a separate day (median [interquartile range, IQR] difference 28[37] days), vibration-controlled transient elastography (VCTE with M/XL probes) was performed after a 3-hour fast to analyze liver steatosis (continuous attenuation parameter, CAP) and fibrosis (liver stiffness measurement, LSM) [16] using FibroScan® 530 (Echosens, Paris, France) from right-sided central axis line with the patient at supine position (requirement: ten successful measurements and an IQR/median ratio <30%). We used 288 and 302 dB/m as cut-off values for CAP [17,18] to qualitatively estimate SLD (Table S6).

Laboratory tests

The DIREVA lab-1/2 tests were analyzed by the Vaasa Central Hospital Laboratory or their subcontracters. B-HbA1c was analyzed using Cobas 501 (Tina-quant Hemoglobin A1c Gen.3 Whole Blood Application, Roche Diagnostics, Mannheim, Germany). If missing, the HbA1c result from a date nearest to registration date was obtained from the laboratory database (median 0 [IQR 59] days, 80%/89% within 100/365 days of other measurements). GADA and IA-2A were analyzed using Elisa (RSR Limited, Cardiff, UK), and free fatty acids (FFA) using NEFA-HR(2) Assay (Fujifilm Wako chemicals Europe GmbH, Germany). Fasting adipose tissue insulin resistance index (Adipo-IR) was calculated as FFA (mmol/l) x insulin (μU/ml). Glucose was analyzed at the study centre (HemoCue Glucose 201+, HemoCue AB, Ängelholm, Sweden).

S/P-Cpe was analyzed with immunochemical assays (Advia Centaur XPT, Siemens Healthineers AG, Forchheim, Germany; Cobas e801 ECLIA, Roche Diagnostics, Mannheim, Germany). In our

research laboratory, we also analyzed from stored (-20°C) S/P samples glucagon (ELISA 10-1271-01, Mercodia AB, Uppsala, Sweden), lipids (Thermo Indiko, Waltham, Massachusetts, USA), and, for direct comparison of the two time-points and inclusion of insulin-users, C-peptide and insulin (Elecsys Cobas, Roche diagnostics, Mannheim, Germany and Mercodia Iso-insulin ELISA, detecting mainly endogenous or both endogenous and exogenous insulin, respectively; registration: $Group_A$, N=456, $Group_B$, N=121; follow-up: $Group_B$, N=194). Since C-peptide values were analyzed using different assays, a cubic spline was fitted to the values of individuals having measurements taken with both assays, allowing for the smooth estimation of the relationship between the assays. For individuals with only one assay value available, cubic spline imputation (R 4.0.2, Stats Package, smooth.spline function) was then applied to predict their corresponding C-peptide values based on the fitted spline, ensuring a more accurate comparison across the dataset.

HOMA2-B and HOMA2-IR were calculated with the HOMA calculator (V2.2.3, University of Oxford, Oxford, UK) including insulin as pmol/l (1 µU/ml = 6.00 pmol/l) [19] or C-peptide as nmol/l.

As a sensitivity analysis, we calculated the HOMA2-IR ($INS_{endo+exo}$) -index using insulin values measured with the kit detecting both human insulin and insulin analogues. This correlated well with HOMA2-IR calculated with the routine measurements minimally detecting insulin analogues, among the non-insulin users (R=0.93, p=5.0748E-67), but not among the insulin users (R=-0.27, p=0.191).

Statistical analysis

Data are reported as median[IQR] or mean±SD, and variables with skewed distributions were log_e-transformed for linear regression analyzes. Comparisons of continuous variables between subgroups were analyzed using Kruskal-Wallis test, and intragroup changes during the follow-up with related samples Wilcoxon signed rank -test. Analysis of covariance (ANCOVA) was used for

adjusted intergroup comparisons, and Spearman´s rank correlation coefficient for correlations. Multivariable linear regression was conducted using either stepwise forward or enter method. We report Bonferroni-corrected p-values for Kruskal-Wallis and nominal p-values for Wilcoxon signed rank -test and linear regression models (<0.05 considered statistically significant). IBM Statistics SPSS 27.0 was used for statistical analysis.

Data and Resource Availability

For issues of patient confidentiality and restrictions in institutional review board permissions, original de-identified data is only available through specific reasonable request to the corresponding author and material transfer agreement following EU regulations.

RESULTS

Changes in the cluster variables during follow-up and cluster stability (Group$_A$ & Group$_B$)

We compared data collected at registration and at follow-up 4.6[2.8] years (Median[IQR]) later for 547 individuals with diabetes (40 SAID, 16 SIDD, 52 SIRD, 148 MOD, 291 MARD) (Tables S1-S6). Overall, the differences between the subgroups regarding the clustering variables diminished during the follow-up. While HbA1c was initially considerably higher in SIDD than in the other subgroups, this difference attenuated later with a major decrease in SIDD (from 101.6[19.1] to 57.5[19.0] mmol/mol, 11.5[1.8] to 7.4[1.7]%, p=0.000805), and an increase in MARD (from 42.0[8.0] to 44.0[9.0] mmol/mol, 6.0[0.7] to 6.2[0.8]%, p=2.0082E-12) (Table S4, Figure S2). Also, the HOMA2-B reflecting fasting insulin secretion was lowest at registration in the SIDD group but increased during follow-up (from 36.6[25.2] to 60.2[39.9], p=0.0437).

On the other hand, the highest levels of HOMA2-B and HOMA2-IR (reflecting insulin resistance) seen in SIRD at both timepoints decreased significantly in between (151.8[47.2] vs. 103.7[53.9],

p=0.000003; 4.9[2.6] vs. 2.5[1.5], p=1.4827E-7; respectively). This happened despite stable BMI (correlation between decrease in BMI and HOMA2-IR at an individual level, R=0.22, p=0.117), while the minor decrease in HOMA2-IR seen in MOD (from 2.2[1.2] to 2.1[1.1], p=0.027303) correlated with a decrease in BMI (R=0.39, p=7.9976E-7). Data for BMI is shown in Table S2 and S4.

We compared the cluster assignment performed on data at registration and after follow-up (Figure S4, Table S7-S8; SAID excluded, being based on GADA positivity at baseline). While most participants in the MOD (76%) and MARD (91%) groups kept their original cluster, only 13% (N=2/16) in SIDD and 21% (N=11/52) in SIRD group did, mostly reflecting the changes in insulin secretion and resistance described above (Table S8). The reallocated participants mainly moved to the MARD group [8 (50%) of SIDD, 26 (50%) of SIRD, 29 (20%) of MOD]. Compared with those remaining in the original group those reallocated from SIRD to MOD were younger, and those from MOD to MARD older and lost more weight (Table S7).

Different measures of insulin secretion and sensitivity (study visit, Group$_B$)

The fasting measures of insulin secretion (Table 1) correlated only moderately with glucagon-stimulated increase in C-peptide (ΔC-peptide 6-0 min) (fS-C-peptide: R=0.44, p=7.8482E-9; HOMA2-B: R=0.50, p=2.3627E-11). ΔC-peptide was lowest in SAID (0.39[0.51] nmol/l, p<0.02 vs. MARD and SIRD) and SIDD (0.40[0.46] nmol/l) and highest in SIRD (0.98[0.66] nmol/l; p<0.02 vs. SAID, SIDD and MOD) (Table1, Figure S5).

The measures for insulin sensitivity, HOMA2-IR and the glucose disappearance rate (K_{ITT}) (Table 1, Figure S5), correlated only weakly (R=-0.33, p=0.000016). We expected the groups with less insulin-resistance to have the highest K_{ITT}, but that held only for the SAID group (1.86[1.33] %/min) while the SIDD group had the lowest level (1.08[0.57] %/min) (Table 1, Figure S5).

Likewise, after adjusting with FPG and HbA1c, only SAID had better insulin sensitivity than SIRD, MOD and MARD (p<0.03, Figure S6). Of note, despite having a significantly higher HOMA2-IR, the SIRD group did not significantly differ from the other groups (except SAID) with respect to K_{ITT}.

Adipose-tissue insulin resistance (Adipo-IR) was highest in SIRD and lowest in SAID (15.5[10.9] and 4.1[5.8] mmol/l x µU/ml; SIRD vs. SAID/MARD, p<0.03, SAID vs. MOD/ MARD, p<0.002; unchanged after excluding insulin users) (Table 1). At registration, the FFA level was lower in SIRD compared to SAID, MOD and MARD (319[306] vs. 542[212], 602[342], 525[303] mmol/l, p=0.005-8.4822E-8), but not after the follow-up. Also, differing from the other subgroups, FFA and HOMA2-B correlated negatively in SIRD (R=-0.41, p=0.010).

Liver fat content and fibrosis in the subgroups (study visit, Group$_B$)

The liver fat content (CAP) was higher in both SIRD (321[75] dB/m) and MOD (313[75] dB/m) compared with SAID (278[94] dB/m; p<0.005) and MARD (284[73] dB/m; p<0.01) groups (Table 1). These differences disappeared after adjusting with BMI (data not shown). The distribution of the LSM fibrosis measurement followed that of CAP, but with more variance and no significant differences between the groups after adjusting with BMI (unadjusted: SIRD vs SAID; p=0.048372). Nominally, median LSM was highest (7.4[5.3] kPa) and liver fibrosis (LSM>8kPa) most prevalent (42%) in SIRD (Table 1, Figure S8).

We analyzed the BMI-independent association of measures of insulin resistance with CAP and LSM using linear regression (Table S15) within the subgroups. In SIRD, CAP was associated with Adipo-IR (β=0.564, p=0.000447) and K_{ITT} (β=-0.500, p=0.001740) but not with HOMA2-IR. LSM was associated with Adipo-IR and HOMA2-IR in both SIRD (β=0.651, p=0.000460; β=0.424,

p=0.029020, respectively) and MARD (β=0.320, p=0.014657; β=0.304, p=0.019801, respectively), but with K_{ITT} only in MARD (β=-0.474, p=0.000271).

Association of liver steatosis and fibrosis with hepatic, adipose tissue and muscle insulin resistance (study visit, combined Group$_B$)

We then analyzed the determinants of liver fibrosis (presence/absence: LSM $\geq$8/<5 kPa, excluding measures with 5-8 kPa[17]) at the study visit in all patients irrespective of subgroup (Table 2). In a multivariable logistic regression model the presence of liver fibrosis was associated with HOMA2-IR (OR[95% CI] 3.90[2.05-7.42; p<0.001]), Adipo-IR (1.14[1.06-1.022]; p<0.001) and K_{ITT} (0.33[0.17-0.64]; p<0.001), after adjustment with BMI or CAP (Table 2). This was consistent with analysis of covariance: mean[95% CI] K_{ITT} was significantly lower in LSM group $\geq$8 kPa (1.44[1.25-1.64] %/min) compared to <5 kPa (2.11[1.80-2.42] %/min; p=0.002006) group even after adjusting for BMI and other confounding factors. Results using HOMA2-IR and Adipo-IR were similar to K_{ITT} (Figure 2) after excluding insulin users. Also, area under the Receiver Operating Curve increased statistically significantly when HOMA2-IR was added to a model with BMI or CAP in detection of liver fibrosis (AUC[95% CI] 0.73[0.63-0.84] vs. 0.84[0.75-0.92]; 0.75[0.65-0.85] vs. 0.85[0.77-0.93]; respectively, p<0.03 in both, Table 2, Figure S7). On the contrary, at the time of registration, only BMI and SIRD-group, but not HOMA2-IR and Adipo-IR, associated with later presence of liver fibrosis in a univariate logistic regression analysis (Tables S9).

The supplement shows also linear (univariate and multivariable) regression models comparing the effects of the variables for LSM and CAP (Supplement S10-S12). In brief, regarding LSM, Adipo-IR had the strongest association at the study visit and registration in the whole group, while HOMA2-IR had the strongest association when insulin users were excluded. Because HOMA2-IR

and Adipo-IR were to some extent collinear, we examined whether their association with LSM was mediated by fasting insulin. In a separate model (Table S12, Model 7), fasting insulin at the study visit showed the strongest independent association with LSM (β=0.320, p<0.001). On the contrary, BMI had the strongest association with CAP both at the registration (β=0.334, p<0.001) and at the study visit (insulin users included: β=0.334, p<0.001; insulin users excluded β=0.346, p<0.001).

Overall, both CAP and LSM correlated (Spearman) better with HOMA2-IR (R=0.41, p<0.001; R=0.45, p=<0.001, respectively) and Adipo-IR (R=0.41 p<0.001, R=0.39, p<0.001, respectively) than with K_{ITT} (R=-0.25, p=0.001855 and R=-0.33, p=0.000019, respectively). Adipo-IR and HOMA2-IR had a strong correlation (R=0.74, p=1.067E-33). Subgroup-stratified correlations are shown in Tables S13-S14.

CONCLUSIONS

In this regionally representative prospective study on cluster-based subgroups of adult-onset diabetes, we studied the progression of insulin deficiency and sensitivity and evaluated the stability of the subgroup assignment, as well as manifestation of insulin resistance in different tissues, focusing on liver steatosis and fibrosis. We found that, first, the overall differences in the clustering variables between subgroups diminished during the follow-up. Second, membership in the two larger subgroups (MOD, MARD) was relatively stable (with 76-91% remaining in the same cluster) over time, whereas that held true for only 13-21% of the smaller subgroups (SIDD, SIRD) after a median follow-up of 4.6 years. Third, differences between the subgroups in HOMA2 -indices based on fasting measures were not mirrored in the stimulated measures of insulin secretion and sensitivity, particularly regarding insulin resistance. Fourth, the overall prevalence of liver fibrosis among individuals with diabetes was associated with insulin resistance in liver, muscle and adipose

tissue independently of BMI or SLD. However, subgroup-specific differences in SLD and liver fibrosis were mainly explained by BMI.

The changes in cluster assignment were likely affected by two observations: the overall differences between the groups regarding the cluster variables became smaller during the follow-up, and the levels of the variables changed differently among the different subgroups (Table S4). In the insulin-deficient SIDD group we observed a marked decrease in HbA1c accompanied by an increase in HOMA2-B, suggesting that the initial increase in hyperglycemia and deterioration of insulin secretion was partly reversed with commencement of treatment. On the contrary, in all other groups HbA1c increased during the follow-up. We also noted that the HOMA2-indices decreased clearly in SIRD, despite stable BMI, but were stable in MOD despite a decrease in BMI. More frequent use of GLP-1-receptor agonists (GLP1-RA) in MOD (28% vs 9% in SIRD) could explain the decrease in BMI. All in all, glucose levels in SIRD seemed to remain lower with "lighter" treatment compared to MOD.

Keeping in mind the different risk trajectories for comorbidities [2] our data highlights the importance of performing clustering in the early years after diagnosis, since the distinctive features of the subgroups attenuate with time and treatment. While the results support previous data [3] on the stability of the bigger MOD and MARD clusters over time, most participants belonging to the SIDD and SIRD subgroups were reassigned to other clusters. Most of them were regrouped as MARD, increasing its proportion by 13% compared to registration phase. This is a logical consequence of treatment, as individuals in MARD bear the closest resemblance to those without diabetes. Also, most individuals changing the group had been at the cluster borders at registration and shared some characteristics of the 'target' subgroup (Table S7).

The HOMA-indices are increasingly used to estimate insulin sensitivity and secretion. However, having originally been modelled in individuals without diabetes, their performance is affected by hyperglycemia, low C-peptide values [20] and use of exogenous insulin. [21] We compared the HOMA-

indices with results from a combined glucagon–insulin tolerance test (GITT), previously validated against an intravenous glucose tolerance test (IVGTT) and hyperinsulinemic euglycemic clamp (HEC). [15] The glucagon-induced C-peptide secretion correlated moderately to HOMA2-B and resulted in relatively comparable differences between the subgroups as when using the HOMA2-B, similarly to a previous report on IVGTT and HOMA2-B. [3] On the contrary, the HOMA2-IR correlated only weakly with the glucose disappearance rate K_{ITT}, which is not surprising as the HOMA2-IR primarily reflects insulin resistance of the liver [22,23], and K_{ITT} primarily skeletal muscle insulin sensitivity. Thus, differing from a previous study showing a lower glucose disposal rate during HEC in SIRD than in the other groups both at diagnosis and after 5-years [3], our subgroups mainly differed regarding the liver insulin resistance but shared quite similar levels of muscle insulin sensitivity (except for SAID). Besides the different methods to evaluate insulin sensitivity in the studies, the SIRD patients in the HEC cohort had notably higher BMI and HbA1c and the participants were younger with male overrepresentation.

Interestingly, at the registration phase, median FFA level was significantly lower in SIRD than in MOD, but due to the higher fasting insulin in SIRD, the product of FFA x Insulin (Adipo-IR) was approximately similar in both groups. We speculate that the considerably lower FFA level in SIRD could indicate a reasonably effective insulin action in the prevention of lipolysis. [24] High FFA combined with low fasting insulin suggests that dysfunctioning adipose tissue could be the primary defect in MOD, [25] while in SIRD the main defect could lie in the liver insulin resistance. This hypothesis is strengthened by the fact that in SIRD, unlike MOD, fasting insulin secretion (HOMA2-B) correlated with fasting FFA. Another possible explanation for this finding could be metabolic flexibility, that is, body´s ability to switch between using glucose or FFA as an energy source.[26]

The liver fat content measured as CAP was highest in SIRD and MOD, with the differences mostly explained by BMI. The higher prevalence of SLD in these groups is in line with some earlier reports

mainly based on recorded ICD-codes or ALT-values [1,2] but also MRI-data. [3] A previous retrospective study also reported that risk of liver fibrosis was associated with SIRD (although evaluation for fibrosis was restricted to a subset with prior suspicion). [27] In our prospective study, SIRD had highest prevalence and degree of liver fibrosis with a statistically significant difference compared with SAID. Further studies with larger unselected groups are needed to establish or refute the possible association.

Liver fibrosis was associated – independently of weight or liver steatosis - with all measures of insulin resistance: HOMA2-IR and Adipo-IR -indices based on fasting insulin secretion and FFA as well as insulin sensitivity derived from insulin tolerance test (Table 3). In a logistic regression analysis, HOMA2-IR was most strongly associated with liver fibrosis (Table 2), but it did not prospectively predict it. Interestingly, of the measurements at the time of registration, only Adipo-IR and BMI were associated with later liver fibrosis (Table S11), seemingly preceding liver fibrosis. This is in line with a previous study suggesting Adipo-IR to predict the severity of liver fibrosis in individuals with type 2 diabetes and SLD. [28] Taken together, our findings suggest that although BMI and SLD are known contributors to insulin resistance and liver fibrosis, [9,29] they do not comprehensively explain the association between insulin resistance in different organs and liver fibrosis in individuals with diabetes. Of note, the degree of steatohepatitis, which is an important step towards fibrosis, cannot be measured without a biopsy.

Both HOMA2-IR and Adipo-IR -indices incorporate fasting insulin, and hyperinsulinemia has been implicated in liver fibrosis via activation of hepatic stellate cells (HSC), increased collagen-production and accumulation of extracellular matrix (ECM). [30,31] In our study, fasting insulin showed the strongest association with liver fibrosis, when analyzed separately (Table S12, Model 7). However, it remains difficult to discern if high insulin concentration only reflects the overall insulin resistance or if it has an independent role in disease progression.

Previously, treatment options have been quite limited, but the recent update of the guidelines of the American Diabetes Association suggest the use of pioglitazone or GLP1-RA in adults with type 2 diabetes and steatohepatitis or clinically significant liver fibrosis, due to slowing of fibrosis progression and even resolution of steatohepatitis. [11,32,33] Also, sodium-glucose cotransporter 2 (SGLT-2) inhibitors lower liver fat content. [34,35], obesity surgery is efficient in resolution of SLD and steatohepatitis [12], and a thyroid hormone receptor-β agonist resmetirom has shown efficacy in resolution of steatohepatitis and improvement of liver fibrosis. [14] The increasing interventional possibilities highlights the importance of finding individuals at risk of having SLD or its progressed forms.

Strengths of this study include broad regional coverage of the cohort, which was one of the original cohorts reporting the subtypes [1] and the prospective study setting. Using VCTE to estimate liver steatosis and fibrosis instead of liver biopsy can be considered both a strength and a limitation. VCTE estimates a larger volume of liver than biopsy, and pathological interpretation of liver biopsies can be subjective. Also, VCTE is widely used in clinical practice while only a minority of individuals with SLD ever undergo liver biopsy. On the other hand, despite comprehensive validation studies [16], VCTE may not give the same level of accuracy as liver biopsy, it does not measure steatohepatitis, and a high CAP value may result in exaggerated level of liver fibrosis [36]. However, in our study, adjusting LSM with CAP did not affect the results. Limitations also include the relatively small dataset and vulnerability to statistical type II errors, especially in the SIDD group (n=16). Results of this group should be interpreted with caution. Short follow-up time could be also considered a limitation since the development of liver fibrosis can take decades. [37] Also, we did not follow the use of medications between registration and study visit. We also want to point out that the subgroups defined by hard clustering cannot be directly implemented in the clinic or for individual cases. Instead, their usefulness is in studying patterns and creating hypotheses.

In conclusion, our study showed that although the differences became less distinctive, the subgroups of diabetes still differed in insulin secretion and resistance after few years of disease burden. This burden is emphasized by decreasing HOMA2-B across all subgroups. The association of insulin resistance in different tissues with the occurrence of liver fibrosis, independently from BMI or liver steatosis, as well as the reports on increased risk of comorbidities in the most insulin resistant group (SIRD) irrespective of glucose control [2] speaks for screening for insulin resistance in all individuals with type 2 diabetes. Finally, among the cluster-based subgroups, MOD and MARD are relatively stable, and the trend of shift seems to be especially towards MARD over time. We speculate that the odds of being assigned to the same cluster probably weaken with longer follow-up time, perhaps due to the natural heterogeneity in disease progression and differences in treatments. Although the subgroups used in this study are not comprehensive, they reflect the heterogeneity of the disease and provide a stepping stone for future studies. Controlled randomized trials of different medication strategies as well as prospective studies with longer follow-up would provide more information about subgroups and assistance for clinical decisions in future.

ARTICLE INFORMATION

Acknowledgements

We gratefully acknowledge the contribution of the founder of the DIREVA Study, professor Leif Groop, and the study nurses and research assistants Matleena Lamminaho, Linda Sjölund, Britt Stolpe, and Paula Kokko, as well as the DIREVA and Botnia study groups.

Funding

The Direva Study (A.E.K.) has been supported by the Vasa Hospital District, Ollqvist Foundation, State Research Funding via the Turku University Hospital, Vasa Central Hospital, Jakobstadsnejdens Heart Foundation, the Medical Foundation of Vaasa and the Finnish Medical

Foundation. The study (T.T.) has also been supported by grants from The Folkhälsan Research Foundation, The Sigrid Juselius Foundation, The Academy of Finland, University of Helsinki, Swedish Cultural Foundation in Finland, Finnish Diabetes Research Foundation, Foundation for Life and Health in Finland, Finnish Medical Society, Novonordisk Foundation, and State Research Funding via the Helsinki University Hospital. A.L. and A.K. has been supported by Vaasa Medical Foundation. A.L. has been supported by The Finnish Medical Foundation, Turunmaa Duodecim Foundation, Onni & Hilja Tuovinen Foundation, Jussi Lalli & Eeva Mariapori-Lalli Foundation, Kyllikki & Uolevi Lehikoinen Foundation, Päivikki & Sakari Sohlberg Foundation and State Research Funding via the Turku University Hospital. E.A. has been funded by the Swedish Research Council (2020-02191), Swedish Diabetes Foundation, Swedish Heart-Lung Foundation, Swedish Diabetes Wellness Foundation, Påhlsson Foundation, The European Foundation for the Study of Diabetes and Hjelt Foundation and received funding from AstraZeneca for institutional research collaboration.

Duality of Interest

A.L. reports personal travel grant from Recordati Rare Disease. A.K. reports personal travel grant from Abbvie and Ferring Pharmaceuticals and stock ownership in Orion Pharma Oy.

Author contributions

Prior Presentation

Part of the results has been presented at the annual meeting of the European Association for the Study of Diabetes in 2023. A non–peer-reviewed version of this article was submitted to the MedRxiv preprint server on 1st December 2025.

REFERENCES

1. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol*. 2018;6(5):361-369. doi:10.1016/S2213-8587(18)30051-2

2. Asplund O, Thangam M, Prasad RB, et al. Comorbidities and mortality in subgroups of adults with diabetes with up to 14 years follow-up: a prospective cohort study in Sweden. *Lancet Diabetes Endocrinol*. Published online November 2025. doi:10.1016/S2213-8587(25)00283-9

3. Zaharia OP, Strassburger K, Strom A, et al. Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study. *Lancet Diabetes Endocrinol*. 2019;7(9):684-694. doi:10.1016/S2213-8587(19)30187-1

4. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. *Cell*. 2021;184(10):2537-2564. doi:10.1016/J.CELL.2021.04.015

5. Bae JC, Beste LA, Utzschneider KM. The Impact of Insulin Resistance on Hepatic Fibrosis among United States Adults with Non-Alcoholic Fatty Liver Disease: NHANES 2017 to 2018. *Endocrinology and Metabolism*. 2022;37(3):455-465. doi:10.3803/ENM.2022.1434

6. Mantovani A, Csermely A, Petracca G, et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. *Lancet Gastroenterol Hepatol*. 2021;6(11):903-913. doi:10.1016/S2468-1253(21)00308-3

7. Simon TG, Roelstraete B, Khalili H, Hagström H, Ludvigsson JF. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. *Gut*. 2021;70(7):1375-1382. doi:10.1136/GUTJNL-2020-322786

8. Misra S, Wagner R, Ozkan B, et al. Precision subclassification of type 2 diabetes: a systematic review. *Communications medicine*. 2023;3(1). doi:10.1038/S43856-023-00360-3

9. Perry RJ, Samuel VT, Petersen KF, Shulman GI. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. *Nature 2014 510:7503*. 2014;510(7503):84-91. doi:10.1038/NATURE13478

10. Tobias DK, Merino J, Ahmad A, et al. Second international consensus report on gaps and opportunities for the clinical translation of precision diabetes medicine. *Nature Medicine 2023 29:10*. 2023;29(10):2438-2457. doi:10.1038/s41591-023-02502-5

11. Elsayed NA, Aleppo G, Aroda VR, et al. 4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023. *Diabetes Care*. 2023;46(Suppl 1):s49. doi:10.2337/DC23-S004

12. Fakhry TK, Mhaskar R, Schwitalla T, Muradova E, Gonzalvo JP, Murr MM. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. *Surg Obes Relat Dis*. 2019;15(3):502-511. doi:10.1016/J.SOARD.2018.12.002

13. Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. *Gastroenterology*. 2015;149:367-378.e5. doi:10.1053/j.gastro.2015.04.005

14. Harrison SA, Bedossa P, Guy CD, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. *New England Journal of Medicine*. 2024;390:497-509. doi:10.1056/nejmoa2309000

15. Dorkhan M, Tripathy D, Malm G, Asgharian H, Tuomi T, Groop L. Independent measures of insulin secretion and insulin sensitivity during the same test: The glucagon-insulin tolerance test. *J Intern Med*. 2008;264(1):62-71. doi:10.1111/j.1365-2796.2008.01921.x

16. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2019;156(6):1717-1730. doi:10.1053/j.gastro.2019.01.042

17. Eddowes PJ, Sasso M, Allison M, et al. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. *Gastroenterology*. 2019;156:1717-1730. doi:10.1053/j.gastro.2019.01.042

18. Caussy C, Alquiraish MH, Nguyen P, et al. Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis. *Hepatology*. 2018;67:1348-1359. doi:10.1002/hep.29639

19. Knopp JL, Holder-Pearson L, Chase JG. Insulin Units and Conversion Factors: A Story of Truth, Boots, and Faster Half-Truths. *J Diabetes Sci Technol*. 2019;13(3):597. doi:10.1177/1932296818805074

20. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care*. 2004;27(6):1487-1495. doi:10.2337/DIACARE.27.6.1487

21. Kettunen JLT, Tuomi T. Human Physiology of Genetic Defects Causing Beta-cell Dysfunction. *J Mol Biol*. 2020;432(5):1579-1598. doi:10.1016/J.JMB.2019.12.038

22. Ter Horst KW, Gilijamse PW, Ackermans MT, et al. Impaired insulin action in the liver, but not in adipose tissue or muscle, is a distinct metabolic feature of impaired fasting glucose in obese humans. *Metabolism*. 2016;65:757-763. doi:10.1016/j.metabol.2016.02.010

23. Santoleri D, Titchenell PM. Resolving the Paradox of Hepatic Insulin Resistance. *CMGH.Elsevier Inc*. 2019;7:447-456. doi:10.1016/j.jcmgh.2018.10.016

24. Groop LC, Bonadonna RC, DelPrato S, et al. Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus. Evidence for multiple sites of insulin resistance. *J Clin Invest*. 1989;84(1):205-213. doi:10.1172/JCI114142

25. Pellegrinelli V, Carobbio S, Vidal-Puig A. Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues. *Diabetologia*. 2016;59(6):1075-1088. doi:10.1007/S00125-016-3933-4

26. Goodpaster BH, Sparks LM. Metabolic Flexibility in Health and Disease. *Cell Metab.Cell Press.* 2017;25:1027-1036. doi:10.1016/j.cmet.2017.04.015

27. Otero Sanchez L, Zhan CY, Gomes da Silveira Cauduro C, et al. A machine learning-based classification of adult-onset diabetes identifies patients at risk of liver-related complications. *JHEP Reports.* 2023;5(8):100791. doi:10.1016/J.JHEPR.2023.100791

28. Kalavalapalli S, Leiva EG, Lomonaco R, et al. Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD. *J Clin Endocrinol Metab.* 2023;108(5):1192-1201. doi:10.1210/CLINEM/DGAC660

29. Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. *Cell.* 2021;184(10):2537-2564. doi:10.1016/J.CELL.2021.04.015

30. Harrison SA, Dubourg J, Knott M, Colca J. Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction–associated steatotic liver disease. *Hepatology.* Published online 2023. doi:10.1097/hep.0000000000000710

31. Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: Mechanistic concepts and therapeutic perspectives. *Cells.* Preprint posted online 2020. doi:10.3390/cells9040875

32. Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. *N Engl J Med.* Published online April 2025. doi:10.1056/NEJMoa2413258

33. Belfort R, Harrison SA, Brown K, et al. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis. *New England Journal of Medicine.* 2006;355:2297-2307. doi:10.1056/nejmoa060326

34. Latva-Rasku A, Honka MJ, Kullberg J, et al. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients. *Diabetes Care.* 2019;42(5):931-937. doi:10.2337/DC18-1569

35. Kahl S, Gancheva S, Straßburger K, et al. Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial. *Diabetes Care.* 2020;43(2):298-305. doi:10.2337/DC19-0641

36. Petta S, Wong VWS, Cammà C, et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with nonalcoholic fatty liver disease accounting for controlled attenuation parameter values. *Hepatology.* 2017;65:1145-1155. doi:10.1002/hep.28843

37. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. *Nature Publishing Group.* 2013;10:330-344. doi:10.1038/nrgastro.2013.41

TABLES

Table 1. Clinical characteristics of the patients participating in the study visit (Group$_B$) 5.9 (95% CI 5.6-6.3) years after diagnosis, stratified by the cluster-based subgroup at registration

n=194	SAID (n=29)	SIDD (n=11)	SIRD (n=35)	MOD (n=51)	MARD (n=68)
Age years	61.3 (25.3)	66.5 (15.8)	68.3 (10.6)	59.2 (18.6)	71.4 (8.3)
Duration years	6.8 (2.5)	5.9 (4.3)	6.3 (2.8)	5.9 (3.5)	5.3 (2.2)
BMI kg/m2	27.8 (6.5)	30.2 (4.1)	33.3 (5.2)	34.9 (6.6)	27.6 (4.8)
HbA1c mmol/mol	55.0 (23.0)	59.0 (21.0)	43.0 (9.0)	47.0 (8.0)	45.5 (10.0)
HbA1c %	7.2 (2.1)	7.5 (1.9)	6.1 (0.8)	6.5 (0.7)	6.3 (0.9)
Fasting glucose mmol/l	8.5 (4.1)	9.2 (3.9)	6.6 (1.5)	6.9 (2.1)	6.9 (1.7)
Fasting C-peptide nmol/l	0.61 (0.73)	0.95 (0.44)	1.47 (0.83)	1.20 (0.55)	1.08 (0.62)
Fasting Insulin µU/ml	4.4 (9.3)	12.4 (10.4)	22.7 (12.2)	15.6 (12.0)	13.7 (12.2)
HOMA2-B	41.1 (60.9)	55.4 (23.7)	134.4 (78.9)	96.3 (51.5)	90.4 (48.6)
HOMA2-IR	1.6 (1.6)	2.5 (1.3)	3.5 (2.2)	2.9 (1.6)	2.7 (1.6)
FFA mmol/l	642 (357)	530 (360)	676 (218)	705 (235)	649 (243)
Adipo-IR mmol/lxµU/ml	4.1 (5.8)	7.3 (6.2)	15.5 (10.9)	10.0 (13.3)	7.7 (10.2)
C-peptide response nmol/l*	0.39 (0.51)	0.40 (0.46)	0.98 (0.66)	0.50 (0.54)	0.72 (0.39)
C-peptide 6 min nmol/l †	1.06 (1.01)	1.54 (0.56)	2.51 (1.00)	1.81 (0.81)	1.88 (0.82)

K_{ITT} %/min	1.86 (1.33)	1.08 (0.57)	1.64 (1.02)	1.68 (1.01)	1.64 (1.04)
CAP dB/m	278 (94)	303 (78)	321 (75)	313 (75)	284 (73)
LSM kPa	5.5 (2.2)	6.9 (3.6)	7.4 (5.3)	7.0 (4.6)	6.2 (3.1)
LSM ≥8kPa, % (n)	17 (4)	36 (4)	42 (13)	41 (19)	27 (17)
Glucagon ng/l	12.7 (16.2)	22.5 (17.9)	21.9 (14.6)	20.8 (16.0)	18.9 (18.4)
eGFR ml/min	91 (29)	97 (43)	76 (36)	96 (21)	85 (15)
On insulin % (n)	55 (16)	55 (6)	3 (1)	6 (3)	6 (4)
Metformin % (n)	59 (17)	64 (7)	60 (21)	82 (42)	69 (47)
DPP-4i % (n)	14 (4)	36 (4)	14 (5)	16 (8)	15 (10)
SGLT-2i % (n)	14 (4)	55 (6)	34 (12)	35 (18)	24 (16)
GLP-1RA % (n)	3 (1)	46 (5)	9 (3)	28 (14)	7 (5)
Dyslipidemia medication % (n) ‡	31 (9)	64 (7)	71 (25)	61 (31)	68 (46)

The study visit occurred 5.2 (95% CI 4.8-5.8) years after registration. Data are median (IQR). SAID/SIDD/SIRD, Severe autoimmune/insulin-deficient/insulin-resistant diabetes; MOD/MARD, mild obesity-/age-related diabetes; BMI, body mass index; HbA1c, hemoglobin A1c; HOMA2-B and HOMA2-IR, Homeostasis model assessment of β-cell function and insulin resistance (calculated using C-peptide); Adipo-IR, Adipose tissue insulin resistance -index; FFA, Free fatty acid; K_{ITT}, first-order rate constant for glucose disappearance; CAP, continuous attenuation parameter; LSM, Liver stiffness measurement; eGFR, estimated glomerular filtration rate; DPP-4, Dipeptidyl Peptidase 4 inhibitor; SGLT-2i, Sodium-Glucose Transport Protein 2 inhibitors; GLP-1RA, Glucagon-Like Peptide-1 Receptor Agonists. * Change in C-peptide level 6 min after 0,5mg glucagon iv, † C-peptide 6 min after 0.5mg glucagon iv, absolute value, ‡ statin or ezetimibe.

Table 2. Factors associated with liver fibrosis at the study visit (N=92), according to elastography (LSM ≥ 8kPa, n=57 vs. LSM < 5kPa, n=35) in a logistic regression analysis

Univariate	Adjustment								
	No			BMI			CAP		
Variable	OR	p	AUC	OR	p	AUC	OR	p	AUC
Age (years)	1.02 (0.98-1.06)	0.371	0.53 (0.41-0.66)	1.04 (0.99-1.08)	0.119	0.73 (0.63-0.84)	1.05 (1.00-1.0)	0.052468	0.77 (0.67-0.87)
Sex (men)	1.15 (0.49-2.67)	0.751	0.52 (0.40-0.64)	1.27 (0.51-3.15)	0.612	0.73 (0.62-0.84)	0.94 (0.37-2.41)	0.938	0.75 (0.65-0.85)
BMI (kg/m2)	1.16 (1.06-1.27)	0.000844	0.73 (0.62-0.83)	-	-	-	1.10 (0.99-1.21)	0.077456	0.77 (0.67-0.87)
K_{ITT} (%/min)	0.33 (0.17-0.64)	0.000918	0.76 (0.65-0.88)	0.37 * (0.18-0.74)	0.004918 *	0.79 (0.68-0.90)	0.38 (0.19-0.74)	0.004644	0.80 (0.70-0.90)
HOMA2-IR	3.90 (2.05-7.42)	0.000035	0.82 (0.73-0.91)	3.25 (1.63-6.49)	0.000850	0.83 (0.75-0.92)	2.96 (1.55-5.63)	0.000967	0.84 (0.76-0.93)
Adipo-IR (mmol/l x µU/ml)	1.14 (1.06-1.22)	0.000444	0.75 (0.65-0.85)	1.11 (1.03-1.20)	0.004874	0.78 (0.69-0.88)	1.10 (1.02-1.19)	0.011857	0.80 (0.71-0.89)
fS-Insulin$_{endo}$ (µU/ml)	1.12 (1.05-1.18)	0.000326	0.76 (0.67-0.86)	1.10 (1.03-1.17)	0.003379	0.79 (0.69-0.88)	1.09 (1.02-1.16)	0.007187	0.81 (0.72-0.90)

FFA (mmol/dl)	1.002 (1.000-1.004)	0.058053	0.62 (0.50-0.73)	1.001 (0.999-1.003)	0.357678	0.74 (0.63-0.84)	1.001 (0.999-1.003)	0.509847	0.75 (0.65-0.86)
Triglycerides (mmol/l)	2.28 (1.13-4.61)	0.022187	0.63 (0.51-0.74)	1.71 (0.83-3.53)	0.146690	0.75 (0.64-0.85)	1.61 (0.75-3.46)	0.224880	0.76 (0.66-0.86)
Glucagon (ng/l)	1.02 (0.99-1.05)	0.154305	0.63 (0.51-0.75)	1.02 (0.99-1.05)	0.143317	0.74 (0.63-0.84)	1.01 (0.98-1.04)	0.605849	0.74 (0.64-0.85)
HbA1c (mmol/mol)	1.02 (0.98-1.07)	0.302829	0.53 (0.41-0.65)	1.01 (0.97-1.06)	0.611948	0.73 (0.62-0.83)	1.02 (0.97-1.07)	0.509222	0.76 (0.66-0.86)
CAP (dB/m)	1.02 (1.01-1.03)	0.000177	0.74 (0.64-0.85)	1.01 (1.00-1.02)	0.010803	0.77 (0.67-0.87)	-	-	-

Data are shown for OR or AUC with 95% CI. Abbreviations: OR, Odds ratio; LSM, Liver stiffness measurement; SAID/SIDD/SIRD, Severe autoimmune/insulin-deficient/insulin-resistant diabetes; MOD/MARD, mild obesity-/age-related diabetes; BMI, body mass index; K_{ITT}, first-order rate constant for glucose disappearance; ; HOMA2-IR, Homeostasis model assessment of insulin resistance; insulin concentration was analyzed with two methods, one mainly detecting endogenous insulin (INS_{endo}), the other detecting both endogenous insulin and insulin analogues ($INS_{endo+exo}$); FFA, Free fatty acid; HbA1c, hemoglobin A1c; CAP, continuous attenuation parameter. * Note that the i.v. insulin was administered according to the weight (0.05 IU/kg) (see Methods).

FIGURES

Figure 1. Median (95% confidence interval) plasma glucose stratified by diabetes subgroup (a) or the degree of liver stiffness (LSM) (b) during an i.v. glucagon-insulin tolerance test. Glucagon 0,5mg iv and insulin 0,05 IU/kg iv were administered at 0 minutes and 6 minutes, respectively. Number of patients in each group receiving both iv glucagon and insulin: a) SAID n=17, SIDD n=7, SIRD n=28, MOD n=42, MARD n=60; b) LSM <5kPa n=31, LSM 5-7.9 kPa n=65, LSM ≥ 8kPa n=50. Abbreviations: SAID/SIDD/SIRD, Severe autoimmune/insulin-deficient/insulin-resistant diabetes; MOD/MARD, mild obesity-/age-related diabetes. LSM, Liver Stiffness Measurement.

Figure 2. Surrogate measures of insulin resistance on the x-axis (a) K_{ITT}, b) HOMA2-IR and

c) Adipo-IR stratified by the severity of liver fibrosis at the study visit on the y-axis

determined by liver stiffness measurement (< 5kPa, n=35; 5-7.9 kPa, n=84; ≥ 8 kPa, n=57).

Abbreviations: K_{ITT}, first-order rate constant for glucose disappearance; HOMA2-IR, Homeostasis

model assessment of insulin resistance; Adipo-IR, Adipose tissue insulin resistance -index.

*/**/*** = statistically significant difference (p<0.05) in analysis of covariance with no adjustments

for confounding factors/adjustment for age, sex and BMI/adjustment for age sex and BMI after excluding users of exogenous insulin, respectively.